412293-98-2

Usage

Common Use

Pharmaceutical intermediate in the synthesis of various drugs and medications

Salt Form

Derived from 1-(phenylsulfonyl)piperazine by adding hydrochloric acid

Pharmacological Properties

Investigated for its ability to modulate neurotransmitter systems in the brain

Potential Applications

Antidepressant or antipsychotic agent

Safety Precautions

Handle and use with caution due to possible adverse effects and toxicity if not handled properly

Importance

Significant chemical in the pharmaceutical industry for the development of new medications

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 253175-69-8 tert-butyl 4-(phenylsulfonyl)piperazine-1-carboxylate 
• 77278-38-7 4-benzoylpiperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1250276-76-6 C₂₆H₂₆N₄O₄S 
• 1250276-79-9 C₂₆H₂₆N₄O₃S 
• 1361216-10-5 1-(5-bromo-2-pyridinyl)-4-(phenylsulfonyl)piperazine 
• 1361216-09-2 1,1,1,3,3,3-hexafluoro-2-(6-(4-(phenylsulfonyl)-1-piperazinyl)-3-pyridinyl)-2-propanol 
• 16017-63-3 2-(4-(phenylsulfonyl)piperazin-1-yl)ethan-1-ol 
• 1323405-93-1 3-{4-[4-(4-benzenesulfonyl-piperazin-1-ylmethyl)-benzyloxy]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione 

Relevant academic research and scientific papers

HSD17B13 INHIBITORS AND USES THEREOF

Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.

Development of Biarylalkyl Carboxylic Acid Amides with Improved Anti-schistosomal Activity

The parasitic disease schistosomiasis is the cause of more than 200 000 human deaths per year. Although the disease is treatable, there is one major shortcoming: praziquantel has been the only drug used to combat these parasites since 1977. The risk of the emergence of resistant schistosomes is known to be increasing, as a reduced sensitivity of these parasites toward praziquantel has been observed. We developed a new class of substances, which are derived from inhibitors of human aldose reductase, and which showed promising activity against Schistosoma mansoni couples in vitro. Further optimisation of the compounds led to an increase in anti-schistosomal activity with observed phenotypes such as reduced egg production, vitality, and motility as well as tegumental damage and gut dilatation. Here, we performed structure–activity relationship studies on the carboxylic acid moiety of biarylalkyl carboxylic acids. Out of 82 carboxylic acid amides, we identified 10 compounds that are active against S. mansoni at 25 μm. The best five compounds showed an anti-schistosomal activity up to 10 μm and induced severe phenotypes. Cytotoxicity tests in human cell lines showed that two derivatives had no cytotoxicity at 50 or 100 μm. These compounds are promising candidates for further optimisation toward the new anti-schistosomal agents.

C-3 NOVEL TRITERPENE WITH C-17 AMINE DERIVATIVES AS HIV INHIBITORS

The present invention relates to to C-3 novel triterpene with C-17 amine derivatives of formula (I); or pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, R4, R5 and 'n' are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) and process for preparing them, and their use for the treatment of viral diseases and particularly HIV mediated diseases.

SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Synthesis of 2-(4-substitutedsulfonyl piperazin-l-yl-methyl)-3-aryl- quinazolin-4(3H)-one

Reaction of 2-(chloromethyl)-3-arylquinazolin-4(3H)-one 3 with N-BOC piperazine 4 in acetonitrile using K2CO3 and KI, followed by deprotection of BOC group in IPA HC1, gives 3-aryl-2-(piperazin-l-yl) quinazolin-4(3H)-one 6. The latte

ANTIVIRAL PYRIMIDINES

Disclosed herein are novel compounds comprising substituted pyrimidines, pyrazolopyrimtdines, and imidazolopyrimidines, the syntheses thereof, and compositions thereof, including pharmaceutical compositions, comprising the novel pyrimidines, pyrazolopyrimtdines, imidazolpyrimidines and related compounds. Such compounds function to inhibit entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.

AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS

The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.